Vesicle compositions
View Patent ↗Vesicle compositions are provided that comprise a therapeutic compound. The vesicle compositions may be capable of releasing the therapeutic compound in response to the presence of an external trigger. The vesicle compositions may comprise a plurality of biocompatible vesicles. The biocompatible vesicles may comprise a therapeutic compound for treatment of a patient in need thereof, and one or more cross-linkages between two or more of the biocompatible vesicles, each cross-linkage comprising a chemical sensing moiety and a sensed moiety. In some embodiments, the therapeutic compound may be any compound that provides palliative, curative, or otherwise beneficial effects to a patent.
1. A vesicle composition, comprising:
(A) a first liposome composition, comprising:
(1) a first phospholipid;
(2) cholesterol; and
(3) a phospholipid-polyethylene glycol-boronic acid derivative conjugate, comprising:
wherein n=30-60, and
wherein the first liposome composition encapsulates a first therapeutic compound; and
(B) a second liposome composition, comprising:
(1) a second phospholipid;
(2) cholesterol; and
(3) a phospholipid-polyethylene glycol-glycosyl conjugate comprising a glycosyl moiety comprising a glucosyl moiety, a galactosyl moiety, or a mannopyranosidyl moiety,
wherein:
the second liposome composition encapsulates a second therapeutic compound; and
the first liposome composition is cross-linked to the second liposome composition.
2. The vesicle composition of claim 1 , wherein the glycosyl moiety comprises the glucosyl moiety.
3. The vesicle composition of claim 1 , wherein the glycosyl moiety comprises the galactosyl moiety.
4. The vesicle composition of claim 1 , wherein the glycosyl moiety comprises the mannopyranosidyl moiety.
5. The vesicle composition of claim 1 , wherein the first therapeutic compound and the second therapeutic compound each comprises insulin.
6. The vesicle composition of claim 1 , wherein at least one of the first and the second liposome composition releases an amount of its respective therapeutic compound in response to a presence of a sugar.
7. The vesicle composition of claim 6 , wherein the amount of respective therapeutic compound released is dependent upon a concentration of the sugar.
8. The vesicle composition of claim 1 , wherein the first therapeutic compound and the second therapeutic compound are the same.
9. A vesicle composition useful in the treatment of diabetes, comprising:
(A) a first liposome composition, comprising:
(1) a first phospholipid;
(2) cholesterol; and
(3) a phospholipid-polyethylene glycol-boronic acid derivative conjugate, comprising a boronic acid derivative moiety that is less cytotoxic and/or less inflammatory than the boronic acid derivative moiety in its free form, comprising:
wherein n=30-60, and
wherein the first liposome composition encapsulates insulin; and
(B) a second liposome composition, comprising:
(1) a second phospholipid;
(2) cholesterol; and
(3) a phospholipid-polyethylene glycol-glycosyl conjugate comprising a glycosyl moiety comprising a glucosyl moiety, a galactosyl moiety, or a mannopyranosidyl moiety,
wherein:
the second liposome composition encapsulates insulin; and
the first liposome composition is cross-linked to the second liposome composition.
10. The vesicle composition of claim 9 , wherein the boronic acid derivative moiety of the phospholipid-polyethylene glycol-boronic acid derivative conjugate and the glycosyl moiety of the phospholipid-polyethylene glycol-glycosyl conjugate are covalently bonded to each other.
11. A vesicle composition capable of being injected into a patient, comprising:
(A) a first liposome, comprising:
(1) DPPC;
(2) cholesterol; and
(3) a DSPE-PEG-boronic acid derivative conjugate, comprising:
wherein n=30-60, and
wherein the first liposome encapsulates insulin; and
(B) a second liposome, comprising:
(1) DPPC;
(2) cholesterol;
(3) a DSPE-PEG-glucosyl conjugate;
(4) a DSPE-PEG-galactosyl conjugate; and
(5) a DSPE-PEG-mannopyranosidyl conjugate,
wherein:
the second liposome encapsulates insulin; and
the first liposome is cross-linked to the second liposome.
12. The vesicle composition of claim 11 , wherein the first liposome comprises:
(1) 40-70 mole % DPPC;
(2) 20-50 mole % cholesterol; and
(3) 1-15 mole % DSPE-PEG-boronic acid derivative conjugate.
13. The vesicle composition of claim 11 , wherein the first liposome comprises:
(1) about 56.4 mole % DPPC;
(2) about 40 mole % cholesterol; and
(3) about 3.6 mole % DSPE-PEG-boronic acid derivative conjugate.
14. The vesicle composition of claim 11 , wherein the second liposome comprises:
(1) 40-70 mole % DPPC;
(2) 20-50 mole % cholesterol;
(3) 1-15 mole % DSPE-PEG-glucosyl conjugate;
(4) 1-15 mole % DSPE-PEG-galactosyl conjugate; and
(5) 1-15 mole % DSPE-PEG-mannopyranosidyl conjugate.
15. The vesicle composition of claim 11 , wherein the second liposome comprises:
(1) about 56.4 mole % DPPC;
(2) about 40 mole % cholesterol;
(3) about 1.2 mole % DSPE-PEG-glucosyl conjugate;
(4) about 1.2 mole % DSPE-PEG-galactosyl conjugate; and
(5) about 1.2 mole % DSPE-PEG-mannopyranosidyl conjugate.
16. The vesicle composition of claim 11 , wherein a molecule of the DSPE-PEG-boronic acid derivative conjugate of the first liposome is covalently bonded to at least one of a molecule of the DSPE-PEG-glucosyl conjugate, the DSPE-PEG-galactosyl conjugate, and the DSPE-PEG-mannopyranosidyl conjugate of the second liposome.
17. The vesicle composition of claim 11 , wherein at least one of the first and the second liposomes releases an amount of insulin in response to a presence of glucose.